Spots Global Cancer Trial Database for xospata
Every month we try and update this database with for xospata cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia | NCT06022003 | AML, Adult Refractory AML Relapsed Adult ... FLT3-TKD Mutati... FLT3-ITD | AzaCITIDine Ora... Xospata | 18 Years - | French Innovative Leukemia Organisation | |
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia | NCT06022003 | AML, Adult Refractory AML Relapsed Adult ... FLT3-TKD Mutati... FLT3-ITD | AzaCITIDine Ora... Xospata | 18 Years - | French Innovative Leukemia Organisation | |
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation | NCT04691648 | Acute Myeloid L... | Gilteritinib Ex... | 18 Years - | Astellas Pharma Inc |